Repligen purchased 908 Devices’s desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded ...

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its ...

OAK RIDGE, TENNESSEE, JULY 21, 2014 - A mass spectrometer at Oak Ridge labs used to analyze trace levels of radioactive material, allowing scientists to precisely identify it's source. (Photo by ...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an enhanced quantification package for its ...

BOSTON–(BUSINESS WIRE)–908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced updates to its MX908 ...

BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced that it has expanded access to ...

Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are leading companies in the life science tools industry. Despite a long history of success with those firms, I believe ...

Shares of 908 Devices (NASDAQ: MASS) were down 19% as of 11 a.m. ET on Monday. The steep decline came after the maker of handheld and desktop mass spec devices for chemical and biomolecular analysis ...

ARK Invest's recent sales of 908 Devices shares have helped to send the stock to multi-year lows. 908 Devices is seeing decent revenue growth, but large losses and limited financial flexibility raise ...

The latest price target for 908 Devices (NASDAQ:MASS) was reported by Leerink Partners on August 5, 2025. The analyst firm set a price target for $12.00 expecting MASS to rise to within 12 months (a ...

908 Devices Inc. MASS shares ended the last trading session 19.2% higher at $6.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Portfolio includes PAT devices for real-time process monitoring, control and analysis Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and ...